After Early Setback, Sanofi-GSK Vaccine Finds Better Luck In Phase 2 Trials
The initial Phase 1/2 trial suggested the vaccine wasn’t adequately protective in older adults. But new results show that the companies' covid vaccine generates strong levels of antibodies for all adults.